Baseline Characteristics and Treatment Persistence in UK Patients With Moderate-to-Severe UC Following 12-Week Mirikizumab Induction: Real-World Data From IBD BioResource
Author(s)
Tariq Ahmad, D.Phil, MB ChB, FRCP1, Peter Irving, MBBS, MA, MD, FRCP2, Rachael Piper, BSc3, Anna Willis, MPH3, Manya Mirchandani, MSc3, Laetitia T. Pele, PhD4, Mohammed T. Sharip, MBBS, MRCP5, Caroline Casey, BSc, PhD6, Lill-Brith Wium von Arx, MSc, PhD6, Endip Dhesi, MBBS, BSc6, Beatrice Gittens, BSc, PhD6, Miles Parkes, MBBS DM FMedSci5.
1Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, United Kingdom, 2Gastroenterology, Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, United Kingdom, 3Costello Medical, London, United Kingdom, 4NIHR IBD BioResource, Cambridge, United Kingdom, 5Gastroenterology, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom, 6Eli Lilly and Company, Indianapolis, IN, USA.
1Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, United Kingdom, 2Gastroenterology, Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, United Kingdom, 3Costello Medical, London, United Kingdom, 4NIHR IBD BioResource, Cambridge, United Kingdom, 5Gastroenterology, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom, 6Eli Lilly and Company, Indianapolis, IN, USA.
OBJECTIVES: Mirikizumab has demonstrated long-term efficacy and safety in adult patients with moderately-to-severely active ulcerative colitis in the LUCENT clinical trial programme. We present an interim analysis of a retrospective, multicentre observational study describing patient baseline characteristics, prior advanced therapies and treatment persistence at 12 weeks in routine UK clinical practice.
METHODS: Data was prospectively collected by the UK-wide NIHR IBD BioResource of IBD patients (N=78) across 20 NHS sites who initiated mirikizumab treatment for ulcerative colitis and were followed up for 12 weeks. Eligible patients were ≥18 years old, had a diagnosis of moderate-to-severe ulcerative colitis and received at least one dose of mirikizumab. Analyses were descriptive and reported as mean (standard deviation [SD]), median (interquartile range [IQR]) and percentages (%). Kaplan-Meier analysis was used to describe time to discontinuation for N=71 patients.
RESULTS: The majority of patients who initiated mirikizumab treatment were male (59%). Mean (±SD) disease duration was 10.0±8.3 years, 41% had extensive ulcerative colitis and median (IQR) faecal calprotectin was 813.0 µg/mg (1069.0). The proportion of patients with a modified Mayo score of moderate and severe was 33% and 24%, respectively. 29.5% of patients had a Mayo endoscopic subscore of 3 (severe). 85.9% of patients had prior experience with advanced therapies, which included anti-tumour necrosis factor inhibitors (66.7%), vedolizumab (60.3%), Janus kinase inhibitors (28.2%) and ustekinumab (25.6%). 26.9%, 23.1% and 35.9% had experienced 1, 2 and 3 or more prior advanced therapies, respectively. At week 12, treatment persistence was 92%. Reasons for discontinuations included adverse event, primary non-response, or withdrawal for other reasons. (Mayo Score - Copyright Mayo Clinic)
CONCLUSIONS: Induction therapy with mirikizumab was successfully continued through 12 weeks in the majority of patients in a real-world UK cohort.
METHODS: Data was prospectively collected by the UK-wide NIHR IBD BioResource of IBD patients (N=78) across 20 NHS sites who initiated mirikizumab treatment for ulcerative colitis and were followed up for 12 weeks. Eligible patients were ≥18 years old, had a diagnosis of moderate-to-severe ulcerative colitis and received at least one dose of mirikizumab. Analyses were descriptive and reported as mean (standard deviation [SD]), median (interquartile range [IQR]) and percentages (%). Kaplan-Meier analysis was used to describe time to discontinuation for N=71 patients.
RESULTS: The majority of patients who initiated mirikizumab treatment were male (59%). Mean (±SD) disease duration was 10.0±8.3 years, 41% had extensive ulcerative colitis and median (IQR) faecal calprotectin was 813.0 µg/mg (1069.0). The proportion of patients with a modified Mayo score of moderate and severe was 33% and 24%, respectively. 29.5% of patients had a Mayo endoscopic subscore of 3 (severe). 85.9% of patients had prior experience with advanced therapies, which included anti-tumour necrosis factor inhibitors (66.7%), vedolizumab (60.3%), Janus kinase inhibitors (28.2%) and ustekinumab (25.6%). 26.9%, 23.1% and 35.9% had experienced 1, 2 and 3 or more prior advanced therapies, respectively. At week 12, treatment persistence was 92%. Reasons for discontinuations included adverse event, primary non-response, or withdrawal for other reasons. (Mayo Score - Copyright Mayo Clinic)
CONCLUSIONS: Induction therapy with mirikizumab was successfully continued through 12 weeks in the majority of patients in a real-world UK cohort.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO25
Topic
Clinical Outcomes
Topic Subcategory
Clinician Reported Outcomes, Performance-based Outcomes
Disease
Biologics & Biosimilars, Gastrointestinal Disorders, No Additional Disease & Conditions/Specialized Treatment Areas